Neuromodulation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Internal Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electrical Stimulation), External Neuromodulation(Transcutaneous Electrical Nerve Stimulation (TENS), Transcranial Magnetic Stimulation (TMS), Respiratory Electrical Stimulation (RES)), By Application (Spinal Cord Stimulation, Deep Brain Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation, Gastric Electrical Stimulation, Transcutaneous Electrical Nerve Stimulation, Transcranial Magnetic Stimulation, Respiratory Electrical Stimulation), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 7.41 Billion
CAGR (2026-2031)	5.95%
Fastest Growing Segment	Transcutaneous Electrical Nerve Stimulation
Largest Market	North America
Market Size (2031)	USD 10.48 Billion

Market Overview

The Global Neuromodulation Market will grow from USD 7.41 Billion in 2025 to USD 10.48 Billion by 2031 at a 5.95% CAGR. Neuromodulation comprises medical technologies that deliver electrical stimulation or pharmaceutical agents directly to nerves to alter biological activity for therapeutic benefit. The market is primarily driven by an aging global population and the rising prevalence of chronic disorders such as Parkinson’s disease, which create substantial demand for non-opioid pain management solutions. According to the World Health Organization, in 2024, data indicated that over 3 billion people worldwide live with a neurological condition, making these ailments the leading contributor to disability globally and highlighting the immense potential patient base for these interventions.

However, market expansion confronts a significant challenge regarding the high cost of devices and unequal access to specialized medical infrastructure. Stringent regulatory frameworks and limited reimbursement coverage often restrict patient access, particularly in developing regions with resource constraints. This disparity is acute in the workforce and limits the ability to deliver care. According to the World Health Organization, in 2024, high-income countries possessed up to 70 times more neurological professionals per 100,000 people than low-income nations, a gap that significantly impedes widespread market adoption in underserved geographies.

Key Market Drivers

Accelerated technological advancements in next-generation neuromodulation devices are fundamentally altering the therapeutic landscape by enhancing precision and patient outcomes. Manufacturers are prioritizing the integration of sensing technologies and closed-loop systems that adjust stimulation based on real-time neural feedback, thereby addressing previous limitations regarding efficacy and battery life. This innovation trajectory is exemplified by recent regulatory milestones that validate the clinical utility of sensing-enabled capabilities. According to Medtronic, January 2024, in the 'Medtronic First-of-its-Kind Percept RC DBS System Receives FDA Approval' press release, the company received approval for a deep brain stimulation system designed to capture and record brain signals for personalized therapy. Such developments facilitate more targeted interventions, reducing the burden of manual adjustments and significantly improving the quality of care for patients requiring long-term management of movement disorders.

Surging investments in research and development by key market players act as a secondary catalyst, driving rapid commercialization and portfolio expansion through strategic consolidation. Major corporations are actively acquiring specialized firms to broaden their minimally invasive offerings and secure a competitive advantage in high-growth segments like sacral neuromodulation. According to Boston Scientific, January 2024, in the 'Boston Scientific to Acquire Axonics, Inc.' announcement, the corporation entered a definitive agreement to purchase the medical technology firm for an equity value of approximately $3.7 billion. This substantial capital injection reflects the industry's confidence in the long-term profitability of bioelectronic medicine. The sector's financial performance further underscores this growth trajectory; according to Medtronic, in May 2024, their Neuroscience Portfolio generated worldwide revenue of $9.4 billion for the fiscal year, highlighting the immense economic scale and commercial viability characterizing the current market environment.

Download Free Sample Report

Key Market Challenges

The high cost of devices coupled with restrictive reimbursement frameworks constitutes a primary restraint on the global neuromodulation market. Manufacturers face difficulties in securing widespread insurance coverage, as payers often classify these therapies as investigational or require extensive evidence of medical necessity before approval. This financial barrier limits the patient pool significantly, as individuals without comprehensive insurance support cannot afford the substantial out-of-pocket expenses required for the implantation and long-term maintenance of these systems.

This economic pressure is further compounded by reductions in payment rates for healthcare providers, which disincentivizes the adoption of advanced pain management techniques. When compensation for performing these complex procedures decreases, medical facilities are less likely to invest in the necessary equipment or personnel. According to the American Society of Anesthesiologists, in November 2024, the finalized government fee schedule for the upcoming year included a reimbursement reduction of 2.83 percent for physician services, a move that threatens the financial sustainability of practices offering interventional pain therapies. Such fiscal tightening directly hampers the scalability of neuromodulation solutions in the healthcare sector.

Key Market Trends

The advancement of Brain-Computer Interface (BCI) technologies for motor and speech restoration represents a pivotal trend moving the sector beyond traditional symptom management toward functional recovery. Developers are increasingly focusing on implantable systems that interpret neural signals to grant paralyzed patients control over digital devices, thereby addressing severe unmet needs in neurorehabilitation. This progress is substantiated by successful clinical milestones in safety and efficacy for novel endovascular systems. According to Synchron, September 2024, in the 'COMMAND Study Results' announcement, the company confirmed that its permanent BCI implant met the primary safety endpoint with zero device-related serious adverse events observed in six patients over a 12-month evaluation period. These results signal a critical maturation in bioelectronic engineering, positioning BCI as a viable future segment for restoring independence to individuals with paralysis.

Concurrently, the market is experiencing a significant expansion of therapeutic indications into mental health, particularly for treatment-resistant psychiatric conditions. Non-invasive modalities such as Transcranial Magnetic Stimulation (TMS) are gaining rapid commercial traction as providers seek effective, non-drug alternatives for depression and obsessive-compulsive disorder. This rising adoption is reflected in the robust financial growth of dedicated neurostimulation companies. According to BrainsWay, November 2024, in the 'Third Quarter 2024 Financial Results' report, the firm recorded a 26 percent year-over-year increase in quarterly revenue, totaling $10.5 million, primarily driven by the heightened demand for its Deep TMS systems. This trajectory highlights the sector’s successful diversification into high-value psychiatric applications, reducing reliance on traditional pain management and movement disorder revenues.

Segmental Insights

The Transcutaneous Electrical Nerve Stimulation segment is currently recognized as the fastest-growing category in the Global Neuromodulation Market. This accelerated expansion is largely fueled by the rising global demand for non-invasive and drug-free pain management alternatives in response to concerns regarding opioid dependency. Unlike implantable systems, these devices facilitate convenient home-based care, offering patients a cost-effective solution for treating chronic conditions. Additionally, approvals from the U.S. Food and Drug Administration for over-the-counter availability have significantly broadened market access. Consequently, the shift toward self-administered therapy and continuous product innovation establish this segment as the primary driver of market growth.

Regional Insights

North America maintains a dominant position in the global neuromodulation market, driven by a rising prevalence of chronic conditions such as chronic pain and Parkinson’s disease. This leadership is supported by a robust healthcare framework and favorable reimbursement models from the Centers for Medicare & Medicaid Services that facilitate patient access to treatments. Additionally, the region benefits from the strong presence of major medical device manufacturers and consistent product approvals by the U.S. Food and Drug Administration. These factors, combined with extensive clinical research initiatives, ensure North America remains the primary revenue generator in the global sector.

Recent Developments

• In July 2025, Saluda Medical announced the full commercial launch of its EVA Sensing Technology in the United States. This advanced platform is utilized with the company’s Evoke SmartLoop spinal cord stimulation system to provide clinicians with real-time, objective neurophysiological data. By measuring the spinal cord's response to electrical pulses, the technology enables precise neural dosing and allows for continuous therapy optimization based on individual patient needs. The launch underscored the growing importance of bio-sensing data in neuromodulation, facilitating more effective and durable outcomes for patients treating chronic neuropathic pain.
• In February 2025, Globus Medical entered into a definitive agreement to acquire Nevro Corp. in an all-cash transaction valued at approximately $250 million. This strategic move was intended to combine Globus Medical’s robust commercial infrastructure with Nevro’s advanced spinal cord stimulation platforms, including its AI-driven pain management systems. The acquisition aimed to accelerate the market adoption of Nevro’s comprehensive neuromodulation therapies and expand access to life-changing treatments for patients with debilitating chronic pain. The transaction highlighted a significant consolidation in the industry, merging spine and neuromodulation capabilities to deliver integrated patient care solutions.
• In April 2024, Medtronic plc received approval from the U.S. Food and Drug Administration for its Inceptiv closed-loop rechargeable spinal cord stimulation system. This innovative device was the first from the company to feature sensing technology that detects biological signals along the spinal cord and automatically adjusts stimulation in real-time. The system was engineered to maintain consistent therapy settings that adapt to the patient's daily movements and activities, thereby addressing the need for personalized pain management. This approval represented a significant advancement in neuromodulation therapy, offering a more responsive treatment option for individuals suffering from chronic pain.
• In January 2024, Boston Scientific Corporation announced a definitive agreement to acquire Axonics, Inc. for a purchase price of $71 per share in cash, representing an equity value of approximately $3.7 billion. This strategic acquisition was designed to expand Boston Scientific’s urology portfolio by integrating Axonics’ differentiated technologies, including the R20 rechargeable sacral neuromodulation system used to treat bladder and bowel dysfunction. The transaction aimed to strengthen the company's position in the high-growth sacral neuromodulation market and enhance its ability to provide comprehensive, minimally invasive solutions for patients with chronic pelvic health conditions.

Key Market Players

• Medtronic PLC
• NanoGen Healthcare Pvt. Ltd.
• Boston Scientific Corporation
• Abbott Laboratories Ltd.
• Livanova plc
• Nevro Corporation
• Neurosigma PLC.
• Neuropace, INC.
• Soterix Medical Inc.
• Aleva Neurotherapeutics SA

By Type	By Application	By Region
Internal Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electrical Stimulation) External Neuromodulation(Transcutaneous Electrical Nerve Stimulation (TENS) Transcranial Magnetic Stimulation (TMS) Respiratory Electrical Stimulation (RES))	Spinal Cord Stimulation Deep Brain Stimulation Sacral Nerve Stimulation Vagus Nerve Stimulation Gastric Electrical Stimulation Transcutaneous Electrical Nerve Stimulation Transcranial Magnetic Stimulation Respiratory Electrical Stimulation	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Neuromodulation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Neuromodulation Market, By Type:

• Internal Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electrical Stimulation)
• External Neuromodulation(Transcutaneous Electrical Nerve Stimulation (TENS)
• Transcranial Magnetic Stimulation (TMS)
• Respiratory Electrical Stimulation (RES))

• Neuromodulation Market, By Application:

• Spinal Cord Stimulation
• Deep Brain Stimulation
• Sacral Nerve Stimulation
• Vagus Nerve Stimulation
• Gastric Electrical Stimulation
• Transcutaneous Electrical Nerve Stimulation
• Transcranial Magnetic Stimulation
• Respiratory Electrical Stimulation

• Neuromodulation Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE